摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-Chloro-1-(4-(2-morpholino-2-oxoethyl)piperazin-1-yl)ethan-1-one | 900641-12-5

中文名称
——
中文别名
——
英文名称
2-Chloro-1-(4-(2-morpholino-2-oxoethyl)piperazin-1-yl)ethan-1-one
英文别名
2-[4-(2-chloroacetyl)piperazin-1-yl]-1-morpholin-4-ylethanone
2-Chloro-1-(4-(2-morpholino-2-oxoethyl)piperazin-1-yl)ethan-1-one化学式
CAS
900641-12-5
化学式
C12H20ClN3O3
mdl
——
分子量
289.76
InChiKey
YGHXRSQVSHCCID-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.7
  • 重原子数:
    19
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.83
  • 拓扑面积:
    53.1
  • 氢给体数:
    0
  • 氢受体数:
    4

文献信息

  • In vivo engineered cereblon protein
    申请人:Vividion Therapeutics, Inc.
    公开号:US10781239B2
    公开(公告)日:2020-09-22
    Disclosed herein are in vivo engineered cereblon protein and methods of making the same. The in vivo engineered cereblon protein can include a site-specific non-naturally occurring modification at cysteine 287 as set forth in SEQ ID NO:1, or cysteine 286 as set forth in SEQ ID NO:2 or 3, the modification comprising a moiety resulting from an in vivo Michael addition reaction between an exogenous Michael acceptor and the cysteine 287 as set forth in SEQ ID NO:1, or cysteine 286 as set forth in SEQ ID NO:2 or 3.
    本文公开了体内工程化脑龙蛋白及其制造方法。体内工程化脑龙蛋白可包括 SEQ ID NO:1 所列半胱氨酸 287 或 SEQ ID NO:2 或 3 所列半胱氨酸 286 的位点特异性非天然发生修饰,该修饰包括外源迈克尔受体与 SEQ ID NO:1 所列半胱氨酸 287 或 SEQ ID NO:2 或 3 所列半胱氨酸 286 之间的体内迈克尔加成反应产生的分子。
  • IN VIVO ENGINEERED CEREBLON PROTEIN
    申请人:Vividion Therapeutics, Inc.
    公开号:US20200216507A1
    公开(公告)日:2020-07-09
    Disclosed herein are in vivo engineered cereblon protein and methods of making the same. The in vivo engineered cereblon protein can include a site-specific non-naturally occurring modification at cysteine 287 as set forth in SEQ ID NO:1, or cysteine 286 as set forth in SEQ ID NO: 2 or 3, the modification comprising a moiety resulting from an in vivo Michael addition reaction between an exogenous Michael acceptor and the cysteine 287 as set forth in SEQ ID NO:1, or cysteine 286 as set forth in SEQ ID NO: 2 or 3.
查看更多